Efficacy of ketorolac 0.5% ophthalmic solution for controlling the postoperative ınflammation in pediatric cataract surgery
[ N/A ]
Tarih
2013
Dergi Başlığı
Dergi ISSN
Cilt Başlığı
Yayıncı
Erişim Hakkı
info:eu-repo/semantics/openAccess
Özet
Amaç: Pediyatrik katarakt cerrahisinde postoperatif inflamasyonun kontrolünde % 0.5’lik ketorolak oftalmik solüsyon kullanımı- nın güvenlik ve etkinliğinin değerlendirilmesi. Gereç ve Yöntem: Konjenital ve gelişimsel katarakt tanısı alan 41 hastanın 41 gözü çalışma kapsamına alındı. Hastalar preo- peratif ve postoperatif topikal %0.5’lik ketorolak damla alanlar (grup 1) ve almayanlar (grup 2) olmak üzere 2 gruba ayrıldı. Tüm hastalara fakoemülsifikasyon ve katlanabilir arka kamara göz içi lens implantasyonu uygulandı. Kontrol muayeneleri ameliyattan 1, 3, 7 ve 30 gün sonra yapıldı. Postoperatif inflamasyon ya da ilişkili komplikasyonlar olan siklitik membran, göz içi lens lenste prespitatlar, anterior ve posterior sineşi ve optik tutsağı yönünden hastalar biyomikroskop ile değerlendirildi ve karşılaştırıldı. Bulgular: İnflamasyon ön kamaradaki inflamatuar hücreler yönünden değerlendirildiğinde, postoperatif 1, 3 ve 7 gün sonra yapılan muayenelerde grup 1 ve grup 2 arasında belirgin fark vardı (p<.05). İnflamasyona ön kamaradaki flare açısından bakıldı- ğında ise, postoperatif 1 ve 3 gün sonra yapılan muayenelerde grup 1 ve grup 2 arasında belirgin fark vardı (p<.05). Buna karşın postoperatif 7 gün sonra yapılan muayenede gruplar arasında fark gözlenmedi. Grup 2‘deki 6 hastada siklitik membran, posterior sineşi, göz içi lenste prespitatlar ve optik tutsağını içeren inflamasyonla ilişkili komplikasyonlar gelişti. Göz içi basınçlar karşılaş- tırıldığında gruplar arasında fark gözlenmedi. Sonuç: Çocuklarda postoperatif inflamasyonun kontrolünde cerrahiden önce başlanıp ardından postoperatif 1 ay süre boyunca %0.5’lik ketorolak oftalmik solüsyon kullanımı etkin ve güvenilir gözükmektedir.
Purpose: To evaluate the efficacy and safety of ketorolac 0.5% ophthalmic solution to control postoperative inflammation in pedi- atric cataract surgery. Materials and Methods: Forty one eyes of 41 children with congenital or developmental cataract were included in the study. The subjects were assigned to receive topical ketorolac 0.5% ophthalmic solution preoperatively and postoperatively (group 1) or with- out ketorolac 0.5% ophthalmic solution (group 2). Each patient had uneventful phacoemulsification with a placement of a foldable posterior chamber intraocular lens. Follow-up visits were performed 1, 3, 7 and 30 days postoperatively. The postoperative inflam- mation or associated complications such as cyclitic membrane, intraocular lens precipitates, anterior and posterior synechia and optic capture were evaluated for each group by slit-lamp examination and compared. Results: There were significant differences in terms of inflammatory cells in the anterior chamber between group 1 and group 2 at follow-up visits that performed postoperatively 1st, 3rd and 7th day (p<.05). Although significant differences were found between groups in aspect of the flare at postoperative 1st and 3rd day visits (p<.05), there was no significant difference at 7th day visit (p>.05). In 6 patients from group 2 had inflammatory related complications including cyclitic membrane, posterior synechia, intraocular lens precipitates and optic capture. There was not statistically significant difference in terms of intraocular pressure between groups. Conclusion: Ketorolac 0.5% solution seems effective and safe when started before surgery and continued 1 month postoperatively for the treatment of the postoperative inflammation in children.
Purpose: To evaluate the efficacy and safety of ketorolac 0.5% ophthalmic solution to control postoperative inflammation in pedi- atric cataract surgery. Materials and Methods: Forty one eyes of 41 children with congenital or developmental cataract were included in the study. The subjects were assigned to receive topical ketorolac 0.5% ophthalmic solution preoperatively and postoperatively (group 1) or with- out ketorolac 0.5% ophthalmic solution (group 2). Each patient had uneventful phacoemulsification with a placement of a foldable posterior chamber intraocular lens. Follow-up visits were performed 1, 3, 7 and 30 days postoperatively. The postoperative inflam- mation or associated complications such as cyclitic membrane, intraocular lens precipitates, anterior and posterior synechia and optic capture were evaluated for each group by slit-lamp examination and compared. Results: There were significant differences in terms of inflammatory cells in the anterior chamber between group 1 and group 2 at follow-up visits that performed postoperatively 1st, 3rd and 7th day (p<.05). Although significant differences were found between groups in aspect of the flare at postoperative 1st and 3rd day visits (p<.05), there was no significant difference at 7th day visit (p>.05). In 6 patients from group 2 had inflammatory related complications including cyclitic membrane, posterior synechia, intraocular lens precipitates and optic capture. There was not statistically significant difference in terms of intraocular pressure between groups. Conclusion: Ketorolac 0.5% solution seems effective and safe when started before surgery and continued 1 month postoperatively for the treatment of the postoperative inflammation in children.
Açıklama
Anahtar Kelimeler
Göz Hastalıkları
Kaynak
Glokom Katarakt
WoS Q Değeri
Scopus Q Değeri
Cilt
8
Sayı
3
